（文章来源：第一财经） 健之佳公告，公司近日收到实际控制人的一致行动人云南祥群的《关于增持公司股份的告知函》，云南 祥群拟自本公告披露日起6个月内通过上海证券交易所交易系统以集中竞价交易方式增持公司A股股 份，增持总金额5000万元，拟增持股份比例不超过总股本的2%，资金来源为自有资金及股票增持专项 贷款。 ...

人民财讯12月31日电，健之佳（605266）12月31日公告，公司实际控制人的一致行动人云南祥群投资有 限公司(简称"云南祥群")拟自本公告披露日起6个月内通过上交所交易系统以集中竞价交易方式增持公 司A股股份，增持总金额5000万元，资金来源为自有资金及股票增持专项贷款。 ...

Core Viewpoint - The company announced that its actual controller, Lan Bo, through Yunnan Xiangqun, holds 13.8183 million shares, accounting for 8.9414% of the total shares, and together with concerted actors, holds a total of 63.0076 million shares, representing 40.7703% of the total shares [1] Summary by Relevant Sections - **Shareholding Structure** - Lan Bo, the actual controller, holds 13.8183 million shares, which is 8.9414% of the total shares [1] - Together with concerted actions, the total shareholding amounts to 63.0076 million shares, or 40.7703% of the total shares [1] - **Planned Share Buyback** - Yunnan Xiangqun plans to increase its stake in the company through a centralized bidding process on the Shanghai Stock Exchange from January 1, 2026, to June 30, 2026 [1] - The total amount for the buyback is set at 50 million yuan, funded by self-owned funds and a special loan from CITIC Bank not exceeding 45 million yuan, with a term of three years [1] - The buyback will not exceed 2% of the total share capital and will not trigger a mandatory tender offer [1]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]

Group 1 - The pharmacy sector experienced a short-term decline, with stocks such as Shuyupingmin falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, also saw a drop in their stock prices [1]

Group 1 - The pharmacy sector has experienced a short-term decline, with major companies such as Xu Yu Ping Min falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, have also seen declines in their stock prices [1]

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.20% year-to-date, with a recent drop of 2.03% on December 22, 2025, indicating potential challenges in the company's market performance [2][1]. Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. It was listed on December 1, 2020. The company specializes in the retail of health products, including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs (with non-prescription drugs at 39.64% and prescription drugs at 32.96%), 7.44% from medical devices, and smaller percentages from other categories such as health foods and personal care products [2]. Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period, with an average of 10,240 circulating shares per shareholder, which increased by 0.04% [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund holds 7.1 million shares, unchanged from the previous period, while the Guangfa Innovation Upgrade Mixed Fund has exited the top ten list [3].

Group 1 - The core point of the article is that Jianzhijia (605266) announced that as of the date of the announcement, the company has no overdue external guarantees [1] Group 2 - The announcement was made on the evening of December 19 [1] - The company is in compliance with its financial obligations regarding external guarantees [1]

| 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 194,357.40 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 69.48 | | 特别风险提示 | 对外担保总额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近 | | | 一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到 | | | 或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示 | 无 | 证券代码：605266 证券简称：健之佳 公告编号：2025-057 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西健之佳勤康医药销售有限公司 | | --- ...

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.24% year-to-date, with a recent slight recovery in the last five trading days, indicating potential volatility in the market performance of the company [2]. Group 1: Stock Performance - As of December 19, Jianzhijia's stock price decreased by 2.03%, trading at 19.76 yuan per share, with a total market capitalization of 30.54 billion yuan [1]. - The stock has shown a 2.60% increase over the last five trading days and a 0.51% increase over the last 20 days, while it has declined by 8.18% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, reflecting a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down by 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Group 3: Business Overview - Jianzhijia, established on September 27, 2004, and listed on December 1, 2020, operates in the health product retail sector, offering a range of products including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs, with non-prescription drugs accounting for 39.64% and prescription drugs for 32.96% [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in the offline pharmacy segment, and is associated with concepts such as retail pharmacies and family doctor services [2].